Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
published online Aug 11.
Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014, published online Aug 11. http://dx.doi.org/10.1016/S1474-4422(14)70128-0.
Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
Goadsby PJ, Edvinsson L, Ekman R Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988, 23:193-196.
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004, 350:1104-1110.
Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain
Benschop RJ, Collins EC, Darling RJ, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage 2014, 22:578-585.